Loteprednol etabonate shows promise in the treatment of ocular inflammation

被引：0
作者：
不详
机构：
来源：
Drugs & Therapy Perspectives | 1999年 / 13卷 / 4期
关键词：
D O I：
10.2165/00042310-199913040-00001
中图分类号：
学科分类号：
摘要：
Loteprednol etabonate is a well tolerated topical agent that can reduce ocular inflammation occurring as a result of cataract surgery, allergic conjunctivitis or use of contact lenses. The low potential for elevated intraocular pressure with short-term use and apparently good systemic tolerability of loteprednol etabonate are attractive characteristics. However, firm conclusions on the clinical value of the drug cannot be made until direct comparisons with other active treatments are available. © Adis International Limited. All rights reserved.
引用
收藏
页码：1 / 5
页数：4
相关论文
共 18 条
[1]  
Eye drops can cause systemic effects, Drug Ther Perspect, 12, 3, pp. 13-16, (1998)
[2]  
Noble S., Goa K.L., Loteprednol etabonate: Clinical potential in the management of ocular inflammation, BioDrugs, 10, 4, pp. 329-339, (1998)
[3]  
British National Formulary. No. 36, 452, 4, (1998)
[4]  
Abel R., Leopold I.H., Ocular diseases, Avery's Drug Treatment: Principles and Practice of Clinical Pharmacology and Therapeutics. 3rd Ed, (1987)
[5]  
Drug-induced uveitis can usually be easily managed, Drug Ther Perspect, 11, 10, pp. 11-14, (1998)
[6]  
Asbell P.A., Torres M.A., Therapeutic dilemmas in external ocular diseases, Drugs, 42, 4, pp. 606-615, (1991)
[7]  
Stewart R., Horwit B., Howes J., Et al., A double-masked, placebocontrolled evaluation of 0.5% loteprednol etabonate in the treatment of post-operative inflammation, J Cataract Refract Surg, 24, 2, pp. 1480-1489, (1998)
[8]  
The Loteprednol Etabonate Post-operative Inflammation Study Group 2. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of post-operative inflammation, Ophthalmology, 105, 9, pp. 1780-1786, (1998)
[9]  
Bartlett J.D., Howes J.F., Ghormley N.R., Et al., Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis, Curr Eye Res, 12, pp. 313-321, (1993)
[10]  
Asbell P., Howes J., A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis, CLAO J, 23, pp. 31-36, (1997)
12